Alzheimer's disease (AD) is a significant and growing global health challenge, with dementia expected to affect 150 million individuals by 2050. As the primary cause of dementia, AD has profound health, social, and economic implications. Despite the urgent need, effective treatments are lacking, and the disease is often misdiagnosed, especially in primary care settings, where misdiagnosis rates exceed 50%. These inaccuracies in diagnosis delay optimal care and treatment, a critical issue as disease-modifying therapies become more widely available.
The project aims to address the pressing need for improved diagnostic tools to facilitate early and accurate detection of AD. The current gold-standard biomarkers, such as PET imaging and cerebrospinal fluid (CSF) analysis, are effective but face significant barriers, including high costs, invasiveness, and limited accessibility in primary care. Recent advancements in plasma biomarkers and digital cognitive tests offer promising, cost-effective, and scalable alternatives that can address these challenges. However, these tools remain largely unvalidated in unspecialized centers such as primary and secondary care clinics, where the patient population is more diverse and the prevalence of AD is lower compared to specialized memory clinics.
This project will evaluate the utility of plasma biomarkers and digital cognitive tests in 800 participants presenting with cognitive complaints in primary care centers. By comparing these innovative biomarkers to established gold standards, the study seeks to:
Enhance Diagnostic Accuracy: Validate plasma biomarkers' performance in primary care settings, enabling accurate differentiation between AD and other causes of cognitive impairment.
Promote Accessibility and Equity: Develop cost-effective, minimally invasive tools that can be widely implemented across diverse populations, irrespective of socioeconomic or cultural background.
Integrate Digital Solutions: Introduce standardized, self-administered digital cognitive tests that reduce reliance on specialized personnel, allowing for earlier and broader screening.
Improve Clinical Outcomes: Facilitate timely diagnosis and intervention, which is critical for optimizing treatment and care, especially as disease-modifying therapies become accessible.
The project aligns with global priorities to tackle the dementia crisis by enabling earlier, more precise, and equitable AD diagnoses. By focusing on primary and secondary care, where the majority of patients are assessed, this work addresses a critical gap in the current diagnostic pathway. The integration of plasma and digital biomarkers has the potential to revolutionize AD management, extending diagnostic capabilities to resource-limited settings and reducing the societal and economic burden of dementia.
In summary, this project will establish a robust foundation for implementing innovative diagnostic tools in primary care, contributing to a paradigm shift in how AD is detected and managed, ultimately improving outcomes for millions of individuals worldwide.
